NCT03879798 2024-10-10
DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1/2 Terminated
Memorial Sloan Kettering Cancer Center
Cancer Research and Biostatistics Clinical Trials Consortium
SCRI Development Innovations, LLC
United Therapeutics
University of California, Davis
University of Alabama at Birmingham
Pfizer